The gene AKR1C3 impacts the metabolism of exemestane, reducing its effectiveness by converting it into less active forms. Although not fully substantiated by existing pharmacokinetic studies, AKR1C3's role in xenobiotic metabolism and its high expression in cancerous tissues suggest possible interactions with chemotherapy drugs such as docetaxel and doxorubicin, which could influence their efficacy or toxicity.